GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,311.50p
   
  • Change Today:
      11.50p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,300.00
  • Currency: UK Pounds
  • Shares Issued: 4,145.10m
  • Volume: 994,100
  • Market Cap: £54,363m
  • RiskGrade: 129
  • Beta: 0.56

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Emma Walmsley
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director: Anne Beal
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Jesse Goodman
Independent Non-Executive Director: Vishal Sikka
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Hal Barron , Wendy Becker , Jeannie Lee

Contact Details

Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARKFTSE 100FTSE 350FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,311.50p
Change Today 11.50p
% Change 0.88 %
52 Week High 1,812.50
52 Week Low 1,300.00
Volume 994,100
Shares Issued 4,145.10m
Market Cap £54,363m
Beta 0.56
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.16% below the market average48.16% below the market average48.16% below the market average48.16% below the market average48.16% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Price Trend
36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average
18.37% above the sector average18.37% above the sector average18.37% above the sector average18.37% above the sector average18.37% above the sector average
Income
47.15% above the market average47.15% above the market average47.15% above the market average47.15% above the market average47.15% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
5.4% below the market average5.4% below the market average5.4% below the market average5.4% below the market average5.4% below the market average
23.53% above the sector average23.53% above the sector average23.53% above the sector average23.53% above the sector average23.53% above the sector average

What The Brokers Say

Strong Buy 7
Buy 4
Neutral 11
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 15-Nov-24 15-Aug-24
Paid 09-Jan-25 10-Oct-24
Amount 15.00p 15.00p

Trades for 21-Nov-2024

Time Volume / Share Price
12:17 726 @ 1,311.50p
12:17 29 @ 1,311.00p
12:17 160 @ 1,311.50p
12:17 437 @ 1,311.50p
12:17 406 @ 1,311.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page